메뉴 건너뛰기




Volumn 8, Issue SUPPL. 6, 2010, Pages

Reassessing the standard of care in indolent lymphoma: A clinical update to improve clinical practice

(1)  Rummel, Mathias a  

a NONE

Author keywords

Chronic lymphocytic leukemia; CLL; Diffuse large B cell lymphoma; Follicular lymphoma; NHL; Non Hodgkin's lymphoma; SLL; Small lymphocytic lymphoma; Waldenstr m's macroglobulinemia

Indexed keywords

ALLOPURINOL; BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; FLUDARABINE; FOSTAMATINIB DISODIUM; IBRITUMOMAB TIUXETAN; LENALIDOMIDE; LUMILIXIMAB; MITOXANTRONE; MONOCLONAL ANTIBODY; OFATUMUMAB; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE;

EID: 77958453957     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0129     Document Type: Review
Times cited : (12)

References (65)
  • 2
    • 1842413105 scopus 로고    scopus 로고
    • A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
    • The Non-Hodgkin's Lymphoma Classification Project
    • A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918.
    • (1997) Blood , vol.89 , pp. 3909-3918
  • 4
    • 77958475528 scopus 로고    scopus 로고
    • Available at: Accessed May 3, 2010
    • Leukemia & Lymphoma Society. Facts 2009-2010. Available at: http://www.leukemia-lymphoma.org/attachments/National/br-1247234696.pdf. Accessed May 3, 2010.
    • Facts 2009-2010
  • 5
    • 38549100098 scopus 로고    scopus 로고
    • Is lymphoma occurring in the elderly the same disease?
    • Armitage JO. Is lymphoma occurring in the elderly the same disease? Leuk Lymphoma 2008;49:14-16.
    • (2008) Leuk Lymphoma , vol.49 , pp. 14-16
    • Armitage, J.O.1
  • 7
    • 33845517974 scopus 로고    scopus 로고
    • Molecular pathways in follicular lymphoma
    • Bende RJ, Smit LA, van Noesel CJ. Molecular pathways in follicular lymphoma. Leukemia 2007;21:18-29.
    • (2007) Leukemia , vol.21 , pp. 18-29
    • Bende, R.J.1    Smit, L.A.2    Van Noesel, C.J.3
  • 8
    • 58149382688 scopus 로고    scopus 로고
    • Classification of lymphoid neoplasms: The microscope as a tool for disease discovery
    • Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008;112:4384-4399.
    • (2008) Blood , vol.112 , pp. 4384-4399
    • Jaffe, E.S.1    Harris, N.L.2    Stein, H.3    Isaacson, P.G.4
  • 9
    • 77949453079 scopus 로고    scopus 로고
    • The 2008 WHO classification of lymphomas: Implications for clinical practice and translational research
    • Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009;113:523-531.
    • (2009) Hematology Am Soc Hematol Educ Program , vol.113 , pp. 523-531
    • Jaffe, E.S.1
  • 10
    • 48149103434 scopus 로고    scopus 로고
    • Non-MALT marginal zone lymphomas
    • Thieblemont C. Non-MALT marginal zone lymphomas. Ann Oncol 2008;19(Suppl 4):70-73.
    • (2008) Ann Oncol , vol.19 , Issue.SUPPL. 4 , pp. 70-73
    • Thieblemont, C.1
  • 11
    • 60849139137 scopus 로고    scopus 로고
    • Current treatment options for Waldenström macroglobulinemia
    • Vijay A, Gertz MA. Current treatment options for Waldenström macroglobulinemia. Clin Lymphoma Myeloma 2008;8:219-229.
    • (2008) Clin Lymphoma Myeloma , vol.8 , pp. 219-229
    • Vijay, A.1    Gertz, M.A.2
  • 12
    • 62449324950 scopus 로고    scopus 로고
    • Follicular lymphoma in the United States: First report of the national LymphoCare study
    • Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009;27:1202-1208.
    • (2009) J Clin Oncol , vol.27 , pp. 1202-1208
    • Friedberg, J.W.1    Taylor, M.D.2    Cerhan, J.R.3
  • 13
    • 34249726129 scopus 로고    scopus 로고
    • How I treat indolent lymphoma
    • Gribben JG. How I treat indolent lymphoma. Blood 2007;109:4617-4626.
    • (2007) Blood , vol.109 , pp. 4617-4626
    • Gribben, J.G.1
  • 14
    • 77958482397 scopus 로고    scopus 로고
    • A phase III study of rituximab plus CVP versus CVP alone in patients with previously untreated advanced follicular lymphoma: Updated results with 53 months" median follow-up and analysis of outcomes according to baseline prognostic factors
    • In press
    • Marcus RE, Imrie K, Solal-Celigny P, et al. A phase III study of rituximab plus CVP versus CVP alone in patients with previously untreated advanced follicular lymphoma: updated results with 53 months" median follow-up and analysis of outcomes according to baseline prognostic factors. J Clin Oncol, In press.
    • J Clin Oncol
    • Marcus, R.E.1    Imrie, K.2    Solal-Celigny, P.3
  • 15
    • 28544435078 scopus 로고    scopus 로고
    • Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
    • Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-3732.
    • (2005) Blood , vol.106 , pp. 3725-3732
    • Hiddemann, W.1    Kneba, M.2    Dreyling, M.3
  • 16
    • 34249704600 scopus 로고    scopus 로고
    • Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis
    • Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706-714.
    • (2007) J Natl Cancer Inst , vol.99 , pp. 706-714
    • Schulz, H.1    Bohlius, J.F.2    Trelle, S.3
  • 17
    • 0033968522 scopus 로고    scopus 로고
    • European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
    • Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18:317-324.
    • (2000) J Clin Oncol , vol.18 , pp. 317-324
    • Foran, J.M.1    Rohatiner, A.Z.2    Cunningham, D.3
  • 18
    • 0034999927 scopus 로고    scopus 로고
    • CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia
    • Treon SP, Agus DB, Link B, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother (1991) 2001;24:272-279.
    • (2001) J Immunother (1991) , vol.24 , pp. 272-279
    • Treon, S.P.1    Agus, D.B.2    Link, B.3
  • 20
    • 19944429446 scopus 로고    scopus 로고
    • Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
    • DOI 10.1182/blood-2004-03-0796
    • Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53. (Pubitemid 40053062)
    • (2005) Blood , vol.105 , Issue.1 , pp. 49-53
    • Byrd, J.C.1    Rai, K.2    Peterson, B.L.3    Appelbaum, F.R.4    Morrison, V.A.5    Kolitz, J.E.6    Shepherd, L.7    Hines, J.D.8    Schiffer, C.A.9    Larson, R.A.10
  • 21
    • 77958510526 scopus 로고    scopus 로고
    • First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study group
    • abstract. Presented at the Abstract 535
    • Hallek MS, Fingerle-Rowson G, Fink AM, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study group [abstract]. Presented at the 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana. Abstract 535.
    • 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana
    • Hallek, M.S.1    Fingerle-Rowson, G.2    Fink, A.M.3
  • 22
    • 33749545033 scopus 로고    scopus 로고
    • Rituximab maintenance improves clinical outcome of relapsed/refractory follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial
    • van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/refractory follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-3301.
    • (2006) Blood , vol.108 , pp. 3295-3301
    • Van Oers, M.H.1    Klasa, R.2    Marcus, R.E.3
  • 23
    • 33845515497 scopus 로고    scopus 로고
    • Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
    • Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-4008.
    • (2006) Blood , vol.108 , pp. 4003-4008
    • Forstpointner, R.1    Unterhalt, M.2    Dreyling, M.3
  • 24
    • 60949107711 scopus 로고    scopus 로고
    • Rituximab maintenance for the treatment of patients with follicular lymphoma: Systematic review and meta-analysis of randomized trials
    • Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009;101:248-255.
    • (2009) J Natl Cancer Inst , vol.101 , pp. 248-255
    • Vidal, L.1    Gafter-Gvili, A.2    Leibovici, L.3
  • 26
    • 77958468955 scopus 로고    scopus 로고
    • Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: Results of the PRIMA study
    • abstract. Presented at the Abstract 0557
    • Salles G, Catalano J, Feugier P, et al. Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study [abstract]. Presented at the 2010 Annual Meeting of the European Hematology Association; June 10-13, 2010; Barcelona, Spain. Abstract 0557.
    • 2010 Annual Meeting of the European Hematology Association; June 10-13, 2010; Barcelona, Spain
    • Salles, G.1    Catalano, J.2    Feugier, P.3
  • 27
    • 77958503092 scopus 로고    scopus 로고
    • Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy
    • abstract. Presented at the Abstract 8005
    • Pettengell R, Schmitz N, Gisselbrecht C, et al. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy [abstract]. Presented at the 2010 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2010; Chicago, Illinois. Abstract 8005.
    • 2010 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2010; Chicago, Illinois
    • Pettengell, R.1    Schmitz, N.2    Gisselbrecht, C.3
  • 28
    • 75349085058 scopus 로고    scopus 로고
    • Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: A review of the evidence
    • Morschhauser F, Dreyling M, Rohatiner A, et al. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. Oncologist 2009;14(Suppl 2):17-29.
    • (2009) Oncologist , vol.14 , Issue.SUPPL. 2 , pp. 17-29
    • Morschhauser, F.1    Dreyling, M.2    Rohatiner, A.3
  • 29
    • 55949118446 scopus 로고    scopus 로고
    • Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma
    • Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-5164.
    • (2008) J Clin Oncol , vol.26 , pp. 5156-5164
    • Morschhauser, F.1    Radford, J.2    Van Hoof, A.3
  • 30
    • 33748671762 scopus 로고    scopus 로고
    • Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group protocol S9911
    • Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group protocol S9911. J Clin Oncol 2006;24:4143-4149.
    • (2006) J Clin Oncol , vol.24 , pp. 4143-4149
    • Press, O.W.1    Unger, J.M.2    Braziel, R.M.3
  • 36
    • 34447530283 scopus 로고    scopus 로고
    • Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): A randomised controlled trial
    • UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group
    • Catovsky D, Richards S, Matutes E, et al. UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 2007;370:230-239.
    • (2007) Lancet , vol.370 , pp. 230-239
    • Catovsky, D.1    Richards, S.2    Matutes, E.3
  • 37
    • 33947544426 scopus 로고    scopus 로고
    • Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup phase III trial E2997
    • Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup phase III trial E2997. J Clin Oncol 2007;25:799-804.
    • (2007) J Clin Oncol , vol.25 , pp. 799-804
    • Grever, M.R.1    Lucas, D.M.2    Dewald, G.W.3
  • 38
    • 0037220152 scopus 로고    scopus 로고
    • Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712)
    • Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14.
    • (2003) Blood , vol.101 , pp. 6-14
    • Byrd, J.C.1    Peterson, B.L.2    Morrison, V.A.3
  • 39
    • 19944429446 scopus 로고    scopus 로고
    • Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
    • DOI 10.1182/blood-2004-03-0796
    • Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53. (Pubitemid 40053062)
    • (2005) Blood , vol.105 , Issue.1 , pp. 49-53
    • Byrd, J.C.1    Rai, K.2    Peterson, B.L.3    Appelbaum, F.R.4    Morrison, V.A.5    Kolitz, J.E.6    Shepherd, L.7    Hines, J.D.8    Schiffer, C.A.9    Larson, R.A.10
  • 40
    • 23044510136 scopus 로고    scopus 로고
    • Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
    • Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088.
    • (2005) J Clin Oncol , vol.23 , pp. 4079-4088
    • Keating, M.J.1    O'Brien, S.2    Albitar, M.3
  • 42
    • 70350490537 scopus 로고    scopus 로고
    • How I treat Waldenström macroglobulinemia
    • Treon SP. How I treat Waldenström macroglobulinemia. Blood 2009;114:2375-2385.
    • (2009) Blood , vol.114 , pp. 2375-2385
    • Treon, S.P.1
  • 43
    • 65549105193 scopus 로고    scopus 로고
    • Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
    • Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood 2009;113:3673-3678.
    • (2009) Blood , vol.113 , pp. 3673-3678
    • Treon, S.P.1    Branagan, A.R.2    Ioakimidis, L.3
  • 44
    • 77950464935 scopus 로고    scopus 로고
    • Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia
    • Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1408-1414.
    • (2010) J Clin Oncol , vol.28 , pp. 1408-1414
    • Ghobrial, I.M.1    Gertz, M.2    Laplant, B.3
  • 45
    • 77950487663 scopus 로고    scopus 로고
    • Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia
    • Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1422-1428.
    • (2010) J Clin Oncol , vol.28 , pp. 1422-1428
    • Ghobrial, I.M.1    Hong, F.2    Padmanabhan, S.3
  • 47
    • 63049113411 scopus 로고    scopus 로고
    • Bendamustine: Rebirth of an old drug
    • Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009;27:1492-1501.
    • (2009) J Clin Oncol , vol.27 , pp. 1492-1501
    • Cheson, B.D.1    Rummel, M.J.2
  • 48
    • 77958486743 scopus 로고    scopus 로고
    • Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)
    • abstract Presented at the Abstract 405
    • Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. Presented at the 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana. Abstract 405.
    • 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana
    • Rummel, M.J.1    Niederle, N.2    Maschmeyer, G.3
  • 49
    • 70349330220 scopus 로고    scopus 로고
    • Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia
    • Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378-4384.
    • (2009) J Clin Oncol , vol.27 , pp. 4378-4384
    • Knauf, W.U.1    Lissichkov, T.2    Aldaoud, A.3
  • 50
    • 77749258123 scopus 로고    scopus 로고
    • Clinical Roundtable monograph: Recent advances in NHL
    • Highlights from the 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, Louisiana
    • Czuczman MS, Rummel MJ. Clinical Roundtable monograph: recent advances in NHL. Highlights from the 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, Louisiana. Clin Adv Hematol Oncol 2010;8:A1-11.
    • (2010) Clin Adv Hematol Oncol , vol.8
    • Czuczman, M.S.1    Rummel, M.J.2
  • 51
  • 52
    • 77958515159 scopus 로고    scopus 로고
    • Peripheral blood stem cell mobilization after bendamustine containing chemotherapy in indolent lymphomas is possible. Results from the phase III study of B-R vs. CHOP-R (NHL 1-2003 trial) of the StiL (Study group Indolent Lymphomas, Germany)
    • abstract Presented at the Abstract 2679
    • Burchardt CA, Brugger W, Maschmeyer G, et al. Peripheral blood stem cell mobilization after bendamustine containing chemotherapy in indolent lymphomas is possible. Results from the phase III study of B-R vs. CHOP-R (NHL 1-2003 trial) of the StiL (Study group Indolent Lymphomas, Germany) [abstract]. Presented at the 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana. Abstract 2679.
    • 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana
    • Burchardt, C.A.1    Brugger, W.2    Maschmeyer, G.3
  • 53
    • 73949145763 scopus 로고    scopus 로고
    • Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma
    • Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009;27:5404-5409.
    • (2009) J Clin Oncol , vol.27 , pp. 5404-5409
    • Witzig, T.E.1    Wiernik, P.H.2    Moore, T.3
  • 58
    • 74949083498 scopus 로고    scopus 로고
    • Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics
    • Sher T, Miller KC, Lawrence D, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 2010;51:85-88.
    • (2010) Leuk Lymphoma , vol.51 , pp. 85-88
    • Sher, T.1    Miller, K.C.2    Lawrence, D.3
  • 60
    • 68949135695 scopus 로고    scopus 로고
    • Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180
    • Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009;27:3830-3835.
    • (2009) J Clin Oncol , vol.27 , pp. 3830-3835
    • Treon, S.P.1    Ioakimidis, L.2    Soumerai, J.D.3
  • 62
    • 77958463096 scopus 로고    scopus 로고
    • Ofatumumab in combination with chop (O-CHOP) achieves high response rates in previously untreated follicular lymphoma (FL) patients with high-risk FLIPI scores
    • abstract Presented at the Abstract 0237
    • Czuczman S, Viardot A, Hess G, et al. Ofatumumab in combination with chop (O-CHOP) achieves high response rates in previously untreated follicular lymphoma (FL) patients with high-risk FLIPI scores [abstract]. Presented at the 2010 Annual Meeting of the European Hematology Association; June 10-13, 2010; Barcelona, Spain. Abstract 0237.
    • 2010 Annual Meeting of the European Hematology Association; June 10-13, 2010; Barcelona, Spain
    • Czuczman, S.1    Viardot, A.2    Hess, G.3
  • 64
    • 77958497722 scopus 로고    scopus 로고
    • Promising efficacy with the new anti-cd20 antibody ga101 in heavily pre-treated patients - First results from a phase II study in patients with relapsed/refractory indolent NHL (INHL)
    • abstract Presented at the Abstract 0558
    • Salles A, Morschhauser F, Thieblemont C, et al. promising efficacy with the new anti-cd20 antibody ga101 in heavily pre-treated patients - first results from a phase II study in patients with relapsed/refractory indolent NHL (INHL) [abstract]. Presented at the 2010 Annual Meeting of the European Hematology Association; June 10-13, 2010; Barcelona, Spain. Abstract 0558.
    • 2010 Annual Meeting of the European Hematology Association; June 10-13, 2010; Barcelona, Spain
    • Salles, A.1    Morschhauser, F.2    Thieblemont, C.3
  • 65
    • 77951002653 scopus 로고    scopus 로고
    • Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
    • Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-2585.
    • (2010) Blood , vol.115 , pp. 2578-2585
    • Friedberg, J.W.1    Sharman, J.2    Sweetenham, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.